Lilly's Jaypirca (pirtobrutinib) significantly extended progression-free survival when added to a venetoclax time-limited regimen in patients with previously treated CLL/SLL
Go back to Lilly's Jaypirca (pirtobrutinib) significantly extended progression-free survival when added to a venetoclax time-limited regimen in patients with previously treated CLL/SLL| Lilly (Eli) & Co. (NYSE: LLY) | Delayed: 1102.08 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1102.08 | 52 Week High | $88.16 | |||
| Open | $1102.08 | 52 Week Low | $67.88 | |||
| Day High | $1102.08 | P/E | 255.11 | |||
| Day Low | $1102.08 | EPS | $4.32 | |||
| Volume | 12,115 | |||||
